GlassScriptPhysician profile
Samuel A Yashinsky
NPI 1447637681
$7,453.05
in general payments reported to CMS, 2019-2025
41 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $16.56 · 2021: $152 · 2022: $738 · 2023: $1,566 · 2024: $1,788 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,863.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,186.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $450.37 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $371.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.96 | 2021-2025 | Jardiance, Ofev, Jascayd |
| Amgen INC. | $341.77 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $340.43 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $327.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $285.02 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $234.61 | 2024-2025 | Gemtesa, Myfembree |
| Janssen Pharmaceuticals, INC | $157.67 | 2019-2021 | |
| Astellas Pharma US INC | $152.92 | 2019-2023 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $143.37 | 2024-2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $140.84 | 2022-2025 | Unithroid |
| Abbott Laboratories | $132.46 | 2024-2025 | Freestyle Libre 3 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $110.91 | 2023-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Dexcom, INC. | $91.01 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $86.15 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $84.74 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.67 | 2023-2025 | Xifaxan |
| Dynavax Technologies Corporation | $62.89 | 2023-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $55.84 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $35.71 | 2019-2023 | Strensiq |
| Amarin Pharma, INC. | $31.68 | 2019 | |
| Vanda Pharmaceuticals INC. | $30.78 | 2023 | Hetlioz |
| Ascendis Pharma Endocrinology INC | $29.30 | 2023 | |
| Esperion Therapeutics, INC. | $28.99 | 2023-2024 | Nexletol |
| Ucb, INC. | $27.70 | 2024 | Nayzilam |
| Lundbeck LLC | $24.58 | 2025 | Rexulti |
| Optinose US, INC. | $20.19 | 2024 | |
| Travere Therapeutics, INC. | $17.87 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.82 | 2023 | Edarbi |
| Actelion Pharmaceuticals US, INC. | $17.70 | 2024 | Uptravi, Opsumit |
| Pulmonx Corporation | $16.06 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Biohaven Pharmaceutical Holding Company LTD. | $15.77 | 2022 | |
| Promius Pharma LLC | $15.47 | 2019 | |
| Gilead Sciences, INC. | $14.58 | 2025 | |
| Hikma Pharmaceuticals USA | $14.30 | 2023 | Mitigare |
| Ibsa Pharma INC. | $14.10 | 2023 | Tirosint, Licart |
| Axsome Therapeutics, INC. | $13.92 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Yashinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.